Digestive

[MEDIA ALERT] Fast Food Era - Is This The Demise of A Good Digestive Health?

Retrieved on: 
Montag, Juni 3, 2024
Digestive, Enzyme, Nutrient, Digestion, Nielsen, Absorption, World Gastroenterology Organisation, Animal feed

According to a 2018 Nielsen survey, it is revealed that 76% of Singaporeans choose fast food outlets for a speedy meal.

Key Points: 
  • According to a 2018 Nielsen survey, it is revealed that 76% of Singaporeans choose fast food outlets for a speedy meal.
  • However, the increased consumption of fast food and takeaways has also led to a rise in digestive health issues among the population.
  • To mark World Digestive Health Day on 29 May, LAC is dedicated to raise awareness of digestive health challenges faced by Singaporeans.
  • This can lead to improved nutrient intake, reduced digestive discomfort, and good overall digestive health.

Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH

Retrieved on: 
Dienstag, Mai 21, 2024
Proton, Principal, Bangladesh Technical Education Board, Patient, Pharmacokinetics, MASH, Liver, Liver disease, University, Doctor of Philosophy, Therapy, Armed Forces Medical College, SAN, MBA, UCSD, MD, NIDDK, Magnetic resonance, NAFLD, Magnetic resonance imaging, Division, Digestive, Safety, Kidney, University of California, Hepatology, NIH

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis (MASH) with topline safety and efficacy data anticipated in early Q4 2024. The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.

Key Points: 
  • The company also announced that Dr. Rohit Loomba will serve as Principal Investigator for the study.
  • “Completing enrollment in our first Phase 2a trial is a tremendous accomplishment for the Aligos team,” said Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics.
  • In addition, I’d like to welcome Dr. Rohit Loomba as our Principal Investigator for the HERALD study.
  • “The excellent potency and PK profile makes ALG-055009 a compelling potential treatment option for MASH patients.

New Biomarkers Found to Predict Kidney Failure in Type 1 Diabetes Patients

Retrieved on: 
Mittwoch, Mai 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Hospitals, Paper, Diabetic nephropathy, Patient, Bangladesh Technical Education Board, DNA, Gene expression, Kidney disease, Risk, Dialysis, RNA, Nataraja, Disease, Science Translational Medicine, Death, Genome, Biomarker, Kidney, Methylation, Kidney failure, Genetics, Digestive, Metabolism, Environment, DNA methylation, Pharmaceutical industry

T1D, which affects an estimated 9 million people worldwide, is associated with a significantly increased risk for kidney disease, which can progress to kidney failure.

Key Points: 
  • T1D, which affects an estimated 9 million people worldwide, is associated with a significantly increased risk for kidney disease, which can progress to kidney failure.
  • Failure of the kidneys requires dialysis or renal transplantation and results in higher rates of illness and death for T1D patients.
  • “This has important translational implications for early detection and prevention of kidney failure in at-risk patients with T1D,” Chen said.
  • They plan to validate their findings in larger cohorts of both type 1 and type 2 diabetes patients, with the aim of developing a risk score test for predicting kidney failure in diabetes using several epigenetic biomarkers.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Montag, April 1, 2024
TLI, Diabetes, Immunosuppression, Type 1, Research, Kidney, Hope, Doctor of Philosophy, NIH, Type 1 diabetes, NIDDK, Bangladesh Technical Education Board, UCLA, Digestive, Health, Cell, Organoid, Type 2, Medical device

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

FORTY-THREE PHYSICIANS FROM UNITED DIGESTIVE PARTNER PRACTICES NAMED CASTLE CONNOLLY TOP DOCTORS 2024

Retrieved on: 
Dienstag, April 9, 2024
Education, Journal, Faculty, Castle Connolly Medical, Gastroenterology, Medical research, Digestive, Physician, Health, Nursing

ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.

Key Points: 
  • ATLANTA, April 9, 2024 /PRNewswire/ -- Forty-three physicians from six partner practices of United Digestive have been honored by Castle Connolly as Top Doctors for 2024 for their demonstrated excellence in clinical care, among many other factors.
  • Recipients of the Top Doctors distinction represent the top seven percent of all practicing physicians in the United States.
  • "We are incredibly proud of our 43 physicians who have been recognized as Castle Connolly Top Doctors for 2024," said Dr. Neal C. Patel, CEO of United Digestive.
  • For more information about United Digestive, its partner practices, and Top Doctors recipients, please visit www.uniteddigestive.com .

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Dienstag, März 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Donnerstag, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."

AI Can Speed Design of Health Software

Retrieved on: 
Mittwoch, März 6, 2024
Software design, Engineering, MCIT, Internet, Research, Doctor of Philosophy, Medicine, Population health, Artificial intelligence, Multimedia, Health, Digestive, Language, Exercise, Learning, ChatGPT, Synthetic media, NYU, Kidney, Nursing, NYU Langone Health, Patient, Journal, Intuition, Physician, PAMS, Software, Medical device

NEW YORK, March 6, 2024 /PRNewswire/ --Publishing online March 6 in the Journal of Medical Internet Research, the study examined the capabilities of a form of artificial intelligence (AI) called generative AI or GenAI, which predicts likely options for the next word in any sentence based on how billions of people used words in context on the internet. A side effect of this next-word prediction is that the generative AI "chatbots" like chatGPT can generate replies to questions in realistic language, and produce clear summaries of complex texts.

Key Points: 
  • Led by researchers at NYU Langone Health, the current paper explores the application of ChatGPT to the design of a software program that uses text messages to counter diabetes by encouraging patients to eat healthier and get exercise.
  • The team tested whether AI-enabled interchanges between doctors and software engineers could hasten the development of such a personalized automatic messaging system ( PAMS ).
  • If this proves to be effective at scale it could revolutionize healthcare software design."
  • AI could take software design only so far before human software developers were needed for final code generation, but the overall process was greatly accelerated, say the authors.

Westat Awarded Contract to Continue Supporting the PATH Study

Retrieved on: 
Mittwoch, Februar 21, 2024
Human services, Bangladesh Technical Education Board, PATH, Molina Healthcare, Research, Doctor of Philosophy, CTP, National Institutes of Health, NIH, FDA, Food, Data collection, Digestive, National Cancer Institute, Heated tobacco product, Lung, Kidney, Food and Drug Administration, Center for Tobacco Products, Federal, Public, Knowledge, National library, Behavior, Social science, Partnership, Pharmaceutical industry

ROCKVILLE, Md., Feb. 21, 2024 /PRNewswire/ -- The National Institutes of Health's (NIH's) National Institute on Drug Abuse (NIDA) and the U.S. Food and Drug Administration's (FDA's) Center for Tobacco Products (CTP) have announced the award of a third contract to Westat to continue to support the Population Assessment of Tobacco and Health (PATH) Study. Westat has supported the study since its inception in 2011.

Key Points: 
  • Westat is committed to continuing the trusted partnership with NIH/NIDA and FDA/CTP on the Population Assessment of Tobacco and Health (PATH) Study to understand tobacco use patterns and impacts on public health.
  • Westat has supported the study since its inception in 2011.
  • The PATH Study is a uniquely large, long-term study of tobacco use and health in the United States.
  • "Our work will build on the knowledge we have gained during the past 12 years of supporting the PATH Study and a foundation of over 35 years of tobacco research," notes Charles Carusi, PhD , a Westat Vice President and the project director for the PATH Study.

NYU Langone Health Awarded $13 Million to Create National Center to Promote Diabetes Equity Research

Retrieved on: 
Dienstag, Februar 6, 2024
Olive, Partnership, NYU Langone Health, Digestive, Family, Kidney failure, Public, Prediabetes, Nerve, Research, Health equity, MD, Caregiver, Patient, UCLA, Kidney, Paratriathlon, Olive View–UCLA Medical Center, School, Organization, American Diabetes Association, Social medicine, MPH, Diabetes, Education, AUC, Trust, Bangladesh Technical Education Board, Community, Type 2 diabetes, Workforce, African Americans, Pharmaceutical industry

To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.

Key Points: 
  • To generate more community-engaged diabetes research, the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, has pledged $13 million to NYU Langone Health, Albert Einstein School of Medicine/Montefiore Health System, and UCLA School of Medicine to create the National Center for Engagement in Diabetes Equity Research (CEDER), the first of its kind.
  • Co-led by Nadia Islam, PhD, associate professor in the Institute for Excellence in Health Equity at NYU Langone, CEDER will create a centralized national infrastructure designed to foster community engagement and participation of diverse populations in Type 2 diabetes research.
  • "It is our hope that everyone committed to advancing equity in diabetes research and care can access the support and mentorship they need."
  • CEDER is funded by the National Institute of Diabetes and Digestive and Kidney Diseases.